Unlocking New Frontiers: Daewoong Pharmaceutical and Indonesia Join Forces in Groundbreaking Stem Cell Research and Development
Daewoong Biologics Indonesia Receives GMP Certification for Stem Cell Plant
Daewoong Biologics Indonesia (DBI), a local subsidiary of Daewoong, has announced that its stem cell plant in the Cikarang Javabeka Industrial Complex has received GMP certification from the Indonesian Ministry of Food and Drug Safety and has begun full-scale operations.
A New Era in Stem Cell Research and Development
Park Sung-soo, CEO of Daewoong Pharmaceutical, emphasized the significance of this achievement, stating, “With this GMP certification, Daewoong has taken the first step toward a large-scale research and development project with the Indonesian pharmaceutical and bio industries.” This milestone marks a major turning point in the 20-year relationship between Daewoong and Indonesia.
Addressing the Challenges of an Aging Population
Indonesia’s population is rapidly aging, with over 7% of its citizens now aged 65 and above. This demographic shift has led to an increase in degenerative diseases, such as arthritis, cancer, and brain diseases. In response, Daewoong’s DBI aims to supply high-quality stem cells to 14 hospitals designated by the Indonesian Food and Drug Administration, providing a new hope for patients with intractable diseases.
A Commitment to Innovation and Growth
As an innovation partner, Daewoong seeks to grow together with Indonesia’s pharmaceutical and biotechnology industry. With its advanced biopharmaceutical manufacturing capabilities, human cell management expertise, and cell processing facility license, Daewoong is well-positioned to introduce various stem cells, including umbilical cord-derived stem cells and adipose-derived stem cells, and expand its pipeline to exosomes and immune cells.
A New Era in Stem Cell Therapy
The GMP certification of DBI’s stem cell plant marks a significant milestone in the development of stem cell therapy in Indonesia. With this achievement, Daewoong is poised to play a pivotal role in the stem cell therapy development and production ecosystem, advancing Indonesia’s cutting-edge medical technology and improving the quality of life for its citizens.
Quotes from Key Figures
Taruna Iklar, Indonesia’s Food and Drug Administration Director: “Today, we have established a foundation that will play a pivotal role in the stem cell therapy development and production ecosystem. Our scientists, together with Daewoong’s experts, will advance Indonesia’s cutting-edge medical technology.”
Park Sung-soo, CEO of Daewoong Pharmaceutical: “As an innovation partner, Daewoong seeks to grow together with Indonesia’s pharmaceutical and biotechnology industry. We will do our best to improve the quality of life of Indonesian people by introducing cutting-edge stem cell technologies to Indonesia.”